NASDAQ$LNAI
Lunai Bioworks Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
Renovaro reported a net loss of $7.25 million for the three months ended December 31, 2024, with total operating expenses increasing by 6% compared to the same period last year.
Renovaro Inc. reported a net loss of $7,252,394 for the three months ended December 31, 2024, an increase of 60% from the prior year. Total operating expenses rose by 6% to $4,546,316, primarily driven by an increase in general and administrative expenses, partially offset by a decrease in research and development expenses. The company's cash and cash equivalents stood at $311,764 as of December 31, 2024.
- Net loss for the three months ended December 31, 2024, increased by 60% to $7,252,394.
- Total operating expenses for the three months ended December 31, 2024, increased by 6% to $4,546,316.
- General and administrative expenses increased by 20% to $4,353,123 for the three months ended December 31, 2024.
- Research and development expenses decreased by 74% to $161,084 for the three months ended December 31, 2024.
Headline financials
Revenue & EPS history
Renovaro · Revenue · Quarterly
$0
Forward guidance
Renovaro Inc. anticipates using future funding to satisfy existing obligations, support product commercialization, conduct clinical and regulatory work, and build working capital reserves. The company acknowledges the need for additional funding through equity or debt financing, but cannot assure its availability on acceptable terms.
Tailwinds
- Focus on streamlining overhead and administrative costs to support AI-driven cancer diagnostics platform.
- Intention to secure additional funding through equity or debt financing.
- Expected use of funds for commercialization of products.
- Planned investment in the development and validation of technology.
- Building working capital reserves to support future operations.
Headwinds
- Substantial recurring losses from continuing operations.
- Dependence on additional financing to fund operations.
- No assurance of obtaining funding on reasonable terms.
- Potential for significant additional dilution to stockholders if equity financing is pursued.
- Risk of material reduction or suspension of operations if required funding is not obtained.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2025
+2.0%
Avg return
Earnings day
+2.2%
Avg return
5 days after
+6.9%
Avg return
30 days after
44%
16 / 36 earnings
Positive
+36.6%
Q4 2024
Best reaction
-17.8%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2026 | -7.3% | -18.5% | +9.3% | |
| Q2 2026 | -9.1% | -25.7% | -47.5% | |
| Q1 2026 | +5.1% | +45.6% | +3.9% | |
| Q4 2025 | +30.1% | +1.6% | -25.9% | |
| Q3 2025 | -1.6% | -9.4% | -8.4% | |
| Q2 2025 | -0.9% | -10.1% | -18.5% | |
| Q1 2025 | -17.8% | -21.4% | +192.4% | |
| Q4 2024 | +36.6% | +68.6% | +51.0% | |
| Q3 2024 | -15.3% | -6.7% | +57.7% | |
| Q2 2024 | +4.2% | +18.2% | +65.1% | |
| Q1 2024 | -4.0% | -6.7% | +12.8% | |
| Q4 2023 | +1.8% | +2.9% | -35.1% | |
| Q3 2023 | -3.4% | -16.4% | -36.8% | |
| Q2 2023 | -1.8% | -5.5% | -1.8% | |
| Q1 2023 | -6.0% | -7.8% | -7.8% | |
| Q4 2022 | -12.5% | -9.4% | -35.4% | |
| Q3 2022 | -5.9% | -7.5% | -40.8% | |
| Q2 2022 | +9.9% | +24.0% | +6.7% | |
| Q1 2022 | +7.9% | +11.0% | -18.6% | |
| Q4 2021 | +6.0% | -7.5% | +14.8% | |
| Q4 2020 | -1.6% | -3.1% | -2.4% | |
| Q3 2021 | -6.9% | +1.3% | +58.5% | |
| Q2 2021 | +11.4% | +5.9% | -8.6% | |
| Q2 2020 | -2.2% | +7.1% | +17.3% | |
| Q1 2021 | -0.7% | +2.3% | -2.3% | |
| Q1 2020 | -4.3% | -4.6% | -17.6% | |
| Q4 2019 | +4.8% | +2.5% | -2.8% | |
| Q3 2020 | +4.5% | +12.4% | +28.6% | |
| Q2 2019 | +4.8% | -4.8% | -4.0% | |
| Q1 2019 | +15.5% | +2.6% | +31.3% | |
| Q4 2018 | -0.9% | +4.4% | +8.9% | |
| Q3 2018 | -1.2% | -0.3% | -11.4% | |
| Q2 2018 | +0.7% | +1.0% | -8.2% | |
| Q1 2018 | +0.9% | -0.7% | -2.1% | |
| Q4 2017 | +29.5% | +32.5% | +20.5% | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2017 | +0.0% | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro